Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer
Crossref DOI link: https://doi.org/10.1245/s10434-016-5651-z
Published Online: 2016-11-08
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
De La Cruz, Lucy M.
McDonald, Elizabeth S.
Mick, R.
Datta, Jashodeep
Nocera, Nadia F.
Xu, Shuwen
Fisher, Carla S.
Czerniecki, Brian J.
License valid from 2016-11-08